Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q2 2021 · 10-Q
Revenue$0.00$0.00derived— vs Q2 2020 Net Income-$491.90K-$491.90KN/M vs Q2 2020 EPS Diluted-$0.07-$0.07N/M vs Q2 2020 Operating Income-$231,881N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
Operating Cash Flowderived-$635,981N/M ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end